Shots:

• The P-III 20120215 study involves assessing of Blincyto vs SoC consolidation CT before alloHSCT in pediatric patients with high-risk first relapsed B-cell ALL. The findings were published in JAMA
• Results: @median follow-up 22.4mos.- patients that are alive and event-free (69% vs 43%); patients achieved MRD negative remission (93% vs 24%); @36mos. OS was (81.1% vs 55.8%)
• Additionally- the results from the P-III study COG AALL1331 study evaluating Blincyto in children- adolescents and young adults with first-relapse B-ALL- also published in JAMA. In both studies resulted in less severe toxicities and higher rates of MRD remission

 ­ Ref:  PRNewswire | Image: CNBC